Literature DB >> 27825611

High-sensitivity C-reactive protein in stroke patients - The importance in consideration of influence of multiple factors in the predictability for disease severity and death.

Hong Yu1, Yue Huang2, XinYu Chen3, WenBao Nie3, YongJun Wang4, Yan Jiao2, Guy L Reed5, Weikuan Gu6, Hong Chen7.   

Abstract

High sensitivity C-reactive protein (hsCRP) has been evaluated as a biomarker in stroke and relevant pathological diseases. While its predictive values in several pathological phenotypes have been confirmed, controversy exists among different studies. This review summarizes reports of the predictive values of hsCRP for the diagnosis, etiology, prognosis and mortality of stroke diseases. The current literature suggests that CRP expression is influenced by multiple factors, such as polymorphisms, the genomic backgrounds and gender. However, few reported studies analyzed data based on all these multiple factors. Future studies should focus on comprehensive analysis based on multiple factors.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; High sensitivity C-reactive protein (hsCRP); Ischemic; Polymorphism; Predictability; Stroke

Mesh:

Substances:

Year:  2016        PMID: 27825611     DOI: 10.1016/j.jocn.2016.10.020

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  8 in total

1.  Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys.

Authors:  Eriko Suzuki; Naoko Nishimura; Tetsuya Yoshikawa; Yudai Kunikiyo; Keiko Hasegawa; Keiji Hasumi
Journal:  Pharmacol Res Perspect       Date:  2018-12-05

2.  Inflammation and quality of life in later life: findings from the health, well-being and aging study (SABE).

Authors:  Manuela de Almeida Roediger; Maria de Fátima Nunes Marucci; Etienne Larissa Duim; Jair Lício Ferreira Santos; Yeda Aparecida de Oliveira Duarte; Cesar de Oliveira
Journal:  Health Qual Life Outcomes       Date:  2019-02-06       Impact factor: 3.186

3.  Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.

Authors:  Limin Wang; Di Cao; Huijun Wu; Hongning Jia; Chaoping Yang; Lihua Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

4.  Inflammatory markers as independent predictors for stroke outcomes.

Authors:  Xiao-Guang Zhang; Jie Xue; Wen-Hao Yang; Xu-Shen Xu; Hong-Xian Sun; Liang Hu; Ling-Yun Liu; Yun-Hua Yue
Journal:  Brain Behav       Date:  2020-12-12       Impact factor: 2.708

5.  Association of calprotectin with other inflammatory parameters in the prediction of mortality for ischemic stroke.

Authors:  Juan Marta-Enguita; Manuel Navarro-Oviedo; Idoia Rubio-Baines; Nuria Aymerich; Maria Herrera; Beatriz Zandio; Sergio Mayor; Jose-Antonio Rodriguez; Jose-Antonio Páramo; Estefania Toledo; Maite Mendioroz; Roberto Muñoz; Josune Orbe
Journal:  J Neuroinflammation       Date:  2021-01-05       Impact factor: 8.322

6.  Exploring Cerebrovascular Function in Osteoarthritis: "Heads-up".

Authors:  Baraa K Al-Khazraji; Mark B Badrov; Mason Kadem; Navena R Lingum; Trevor B Birmingham; Joel Kevin Shoemaker
Journal:  Physiol Rep       Date:  2019-10

7.  The association between high-sensitivity C-reactive protein at admission and progressive motor deficits in patients with penetrating artery infarctions.

Authors:  Pengyu Gong; Yukai Liu; Ting Huang; Wenxiu Chen; Teng Jiang; Yachi Gong; Min Lu; Meng Wang; Yingdong Zhang; Xiaohao Zhang; Qiwen Deng; Junshan Zhou
Journal:  BMC Neurol       Date:  2019-12-29       Impact factor: 2.474

8.  Sex differences in the association between self-rated health and high-sensitivity C-reactive protein levels in Koreans: a cross-sectional study using data from the Korea National Health and Nutrition Examination Survey.

Authors:  Se-Won Park; Seong-Sik Park; Eun-Jung Kim; Won-Suk Sung; In-Hyuk Ha; Boyoung Jung
Journal:  Health Qual Life Outcomes       Date:  2020-10-14       Impact factor: 3.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.